Amgen Inc.: enforcement record and regulatory exposure
Amgen Inc. scores 42 out of 100 on the RedFlag Index™ (November 2026), ranking #9 of ten tracked companies, with 3 documented cases of which 2 remain open.
Documented record
2019: Amgen paid $24.75 million over allegations that its copay-charity donations were kickbacks for Sensipar and Kyprolis.
2015: Amgen paid $71 million to 48 states and D.C. over off-label marketing of Enbrel and Aranesp.
2012: Amgen paid $762 million and pleaded guilty to misbranding Aranesp, including a $136 million criminal fine.
Enforcement ledger
| Date | Matter | Amount | Status |
|---|---|---|---|
| December 2023 | FTC Horizon acquisition consent order with monitor | No penalty | Resolved, order in force |
| April 25, 2019 | Copay-charity kickback FCA settlement | $24.8m | Resolved |
| August 2015 | 48-state Enbrel and Aranesp off-label marketing settlement | $71m | Resolved |
| December 2012 | Aranesp guilty plea and resolution incl. $136m criminal fine | $762m | Resolved |
Government enforcement only. Greyed rows are more than ten years old and excluded from scoring under the temporal decay rule.
RegulationWatch coverage
- False Claims Act
Amgen pleaded guilty over Aranesp and paid $762 million. Then it kept paying.
The 2012 plea is a criminal conviction. Further settlements followed within months and continued for years.
- Merger Conditions
Amgen remains bound by FTC bundling ban from Horizon Therapeutics acquisition
The FTC finalised a consent order resolving its challenge, joined by six states, to Amgen's $27.8 billion acquisition of Horizon Therapeutics. The order bars Amgen from bundling its products with Horizon's Tepezza and Krystexxa, requires prior approval for related acquisitions and imposes 15-year compliance obligations under a monitor.
